Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
about
Grapefruit juice-drug interactionsEnterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosisNovel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients.Improving the oral bioavailability of beneficial polyphenols through designed synergies.Factors affecting the absolute bioavailability of nifedipine.Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesReduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.Microsomal quercetin glucuronidation in rat small intestine depends on age and segment.No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juiceIs quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamilThe pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.Effect of Pregnane X Receptor*1B genetic polymorphisms on postoperative analgesia with fentanyl in Chinese patients undergoing gynecological surgery.4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course.Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation.Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartmentsIntestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variationAssociation of genotypes of the CYP3A cluster with midazolam disposition in vivo.Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients.CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation.Effects of Nigella sativa and Lepidium sativum on cyclosporine pharmacokinetics.
P2860
Q24683430-F6555D03-BC78-491B-9C4E-2C3909CFF342Q28367522-A6DF37FD-897F-4018-9A26-5FAAED2DDB08Q31133709-1546C52D-BB74-40C6-A236-A4631083EE82Q33646033-D852EEDD-F5EA-4E78-8E4D-9A99512A3523Q34347120-0D85ACC8-A459-43FA-B341-FCA397A11CAFQ34347670-FA7CBF8E-12E0-494D-B0E0-1C1477D6F7DCQ34657381-E294710B-9025-4405-B6A7-30CA2726C43CQ34659732-DA78505D-4FBC-4784-9CE3-BE1FFC5D7D91Q35000765-9BAB2A32-FD49-4BBA-BC9F-5E840BD8BD9EQ35122803-64271FF0-CCD3-44C6-AC6D-0874DAF9C3EBQ35249663-BF2B2EAB-863A-48B7-91CA-B1263ACB785CQ35803984-1A052855-A89B-4AEB-B556-05541BC66662Q35804217-169129A6-54A4-44EE-BB53-F4D35852C0C3Q35826861-21A35E08-B709-49D3-8448-005188464CD9Q35827133-B01FEAD9-7B94-4C1C-83E3-EA889E49F766Q36053239-22294A9B-0F36-4D9F-9461-91C4076EE59CQ36055486-D35226FA-AA86-43EE-B3A5-F0EC5BC895C7Q36201399-07E8E9A6-F26E-418D-A4EC-AACABBAA427EQ36802040-DE2AB786-6B54-4C47-9E56-2EBC3CE0CC01Q36953191-2B4BC82D-6074-4920-84B3-C8175A68DD1DQ37027004-FFF88348-2149-4691-8701-C080A550D86FQ37148955-D46A355C-175D-4995-9EAF-5BF16E8F51B2Q37154811-1684E37C-8981-4760-A954-4851320DF5D8Q37174004-EC7DEF39-E370-4446-809B-268828EE66E7Q37359687-7F1132C5-B587-4446-B40E-C0C0FE7F4BDDQ37367800-075A3C22-69F4-4FE9-8C46-6063009D514DQ40171742-E75EF363-798C-4E8B-A254-983C80AB61C8Q41596164-9392FC0B-6481-4B5E-8C1E-DBCC11E2E15DQ41813202-AE7232D5-0747-4A00-B7EC-E32F380ABA03Q43065637-3847A5E1-7FDA-4F36-A890-811EFA601D97
P2860
Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
description
1994 nî lūn-bûn
@nan
1994 թուականին հրատարակուած գիտական յօդուած
@hyw
1994 թվականին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Interpatient heterogeneity in ...... y the erythromycin breath test
@ast
Interpatient heterogeneity in ...... y the erythromycin breath test
@en
Interpatient heterogeneity in ...... y the erythromycin breath test
@nl
type
label
Interpatient heterogeneity in ...... y the erythromycin breath test
@ast
Interpatient heterogeneity in ...... y the erythromycin breath test
@en
Interpatient heterogeneity in ...... y the erythromycin breath test
@nl
prefLabel
Interpatient heterogeneity in ...... y the erythromycin breath test
@ast
Interpatient heterogeneity in ...... y the erythromycin breath test
@en
Interpatient heterogeneity in ...... y the erythromycin breath test
@nl
P2093
P1476
Interpatient heterogeneity in ...... y the erythromycin breath test
@en
P2093
J C Kolars
J L Barnett
K E Thummel
P B Watkins
S A Wrighton
P304
P407
P577
1994-11-01T00:00:00Z